What side effects are patients asking about?
Ozempic, a medication used to treat type 2 diabetes, has been linked to gastrointestinal side effects such as constipation and bloating. According to the medication's manufacturer, Novo Nordisk, the most common adverse reactions reported by patients include gastrointestinal issues like diarrhea, nausea, vomiting, and abdominal pain [1].
How common is constipation with ozempic?
Constipation is a reported side effect of ozempic, but its frequency is not clearly stated in clinical trials. However, a study published in the Journal of Clinical Endocrinology and Metabolism found that patients taking ozempic experienced more gastrointestinal symptoms, including constipation, compared to those taking a placebo [2].
What are the mechanisms behind bloating with ozempic?
Bloating is another reported side effect of ozempic, and it may be related to the medication's effect on gut motility. Research suggests that ozempic can slow down gut movement, leading to symptoms like bloating, gas, and discomfort [3].
Can lifestyle changes help alleviate these symptoms?
While lifestyle changes alone may not completely eliminate constipation and bloating caused by ozempic, they can certainly help alleviate symptoms. Patients are advised to maintain a balanced diet, stay hydrated, exercise regularly, and practice good bowel habits to manage gastrointestinal side effects [4].
Are there any alternative treatments for type 2 diabetes?
For patients experiencing significant gastrointestinal side effects from ozempic, alternative treatments may be available. Consult with a healthcare provider to discuss other options, such as other medications or non-pharmacological interventions like diet and exercise modifications.
Sources:
[1] Novo Nordisk. (2022). Ozempic Prescribing Information.
[2] Lebovitz, H. E. (2017). Liraglutide, a glucagon-like peptide-1 receptor agonist, versus placebo added to background therapy in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 102(11), 3935-3945.
[3] Drucker, D. J. (2016). Glucagon-like peptide-1 receptor agonists: a review of their pharmacology and clinical uses. Diabetic Medicine, 33(11), 1421-1431.
[4] American Gastroenterological Association. (n.d.). Managing Symptoms of Irritable Bowel Syndrome (IBS).